Junshi Biosciences

Junshi Biosciences is a Chinese biotech company best known as the developer of Toripalimab, the first domestic PD-1 monoclonal antibody approved in China . The company was co-founded by Feng Hui, who led its R&D operations and production for a decade before departing in 2023 to start AncorBio . Beyond its internal pipeline, Junshi has also engaged in external partnerships: DotBio collaborated with Junshi Biosciences on pipeline programs that had reached IND submission as of mid-2023 , and the partnership was cited alongside DotBio's earlier alliances with Cornerstone Pharmaceuticals and LinkCare Biotechnology as evidence of the company's value . elsewhere's corpus does not cover Junshi's founding date, scale, or current strategic focus beyond these points.